Symbols

PHVS

Pharvaris·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

Consensus Rating "Strong Buy"

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PHVS

Pharvaris N.V.

A clinical-stage company that develops novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks

Industry

Pharmaceutical

Established Date

09/30/2015

Listing Date

02/05/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

129

Fiscal Year Ends

12-31

Website

www.pharvaris.com

Security Type

Common stock

Office address

Emmy Noetherweg 2, 2333 BK Leiden, The Netherlands

Business

Introduction

Pharvaris N.V. was incorporated in the Netherlands on September 30, 2015. The Company is a clinical-stage biopharmaceutical company focused on the development of deucrictibant, an oral small molecule bradykinin B2 receptor antagonist, for the treatment of hereditary angioedema. Its R&D pipeline includes immediate-release capsules for on-demand treatment and sustained-release tablets for prevention, both of which have completed Phase 2 and Phase 3 trials.

Company Financials

EPS

PHVS has released its 2025 Q4 earnings. EPS was reported at -0.72, versus the expected -0.62, missing expectations. The chart below visualizes how PHVS has performed over recent quarters, highlighting trends in earnings surprises.